Neurocrine Biosciences, Inc. (NASDAQ:NBIX) has been assigned an average recommendation of “Buy” from the nineteen ratings firms that are presently covering the company, Marketbeat reports. Seventeen equities research analysts have rated the stock with a buy recommendation and one has given a strong buy recommendation to the company. The average 1 year price objective among brokers that have covered the stock in the last year is $119.25.

A number of analysts recently commented on NBIX shares. Cowen restated a “buy” rating and set a $100.00 price target on shares of Neurocrine Biosciences in a research note on Monday, May 7th. BidaskClub upgraded shares of Neurocrine Biosciences from a “hold” rating to a “buy” rating in a research note on Wednesday, May 9th. Oppenheimer set a $120.00 target price on shares of Neurocrine Biosciences and gave the stock a “buy” rating in a research note on Monday, May 14th. ValuEngine upgraded shares of Neurocrine Biosciences from a “buy” rating to a “strong-buy” rating in a research note on Monday, May 14th. Finally, Barclays set a $100.00 target price on shares of Neurocrine Biosciences and gave the stock a “buy” rating in a research note on Friday, June 8th.

NBIX traded up $0.70 during midday trading on Tuesday, reaching $122.80. The company had a trading volume of 8,270 shares, compared to its average volume of 740,438. The company has a quick ratio of 9.19, a current ratio of 9.19 and a debt-to-equity ratio of 1.00. The stock has a market cap of $10.91 billion, a price-to-earnings ratio of -75.65, a PEG ratio of 34.33 and a beta of 0.33. Neurocrine Biosciences has a 12-month low of $51.42 and a 12-month high of $123.01.

Neurocrine Biosciences (NASDAQ:NBIX) last released its earnings results on Tuesday, July 31st. The company reported ($0.07) earnings per share for the quarter, beating the Zacks’ consensus estimate of ($0.18) by $0.11. The firm had revenue of $96.90 million for the quarter, compared to analysts’ expectations of $84.11 million. Neurocrine Biosciences had a negative net margin of 16.07% and a negative return on equity of 14.22%. The company’s quarterly revenue was up 1428.4% on a year-over-year basis. During the same period in the previous year, the company earned ($0.68) earnings per share. sell-side analysts anticipate that Neurocrine Biosciences will post 0.17 earnings per share for the current year.

In other news, insider Dimitri E. Grigoriadis sold 23,022 shares of the stock in a transaction on Wednesday, August 1st. The shares were sold at an average price of $110.00, for a total value of $2,532,420.00. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, Director Stephen A. Sherwin sold 10,000 shares of the stock in a transaction on Monday, June 11th. The stock was sold at an average price of $98.44, for a total transaction of $984,400.00. Following the completion of the transaction, the director now directly owns 47,548 shares in the company, valued at approximately $4,680,625.12. The disclosure for this sale can be found here. Insiders sold a total of 157,985 shares of company stock worth $16,071,499 in the last three months. Insiders own 4.30% of the company’s stock.

Large investors have recently modified their holdings of the company. Frontier Capital Management Co. LLC grew its holdings in shares of Neurocrine Biosciences by 587.3% during the 1st quarter. Frontier Capital Management Co. LLC now owns 826,272 shares of the company’s stock valued at $68,523,000 after purchasing an additional 706,047 shares during the last quarter. Artisan Partners Limited Partnership grew its holdings in Neurocrine Biosciences by 50.3% in the 1st quarter. Artisan Partners Limited Partnership now owns 1,966,109 shares of the company’s stock worth $163,049,000 after acquiring an additional 657,712 shares during the last quarter. Victory Capital Management Inc. grew its holdings in Neurocrine Biosciences by 86,203.0% in the 1st quarter. Victory Capital Management Inc. now owns 569,600 shares of the company’s stock worth $47,237,000 after acquiring an additional 568,940 shares during the last quarter. Braun Stacey Associates Inc. bought a new stake in Neurocrine Biosciences in the 2nd quarter worth $14,333,000. Finally, BlackRock Inc. grew its holdings in Neurocrine Biosciences by 2.8% in the 1st quarter. BlackRock Inc. now owns 4,908,495 shares of the company’s stock worth $407,061,000 after acquiring an additional 132,749 shares during the last quarter.

Neurocrine Biosciences Company Profile

Neurocrine Biosciences, Inc discovers and develops pharmaceuticals for the treatment of neurological and endocrine-related diseases and disorders in the United States. The company's lead products include INGREZZA (valbenazine), a vesicular monoamine transporter 2 inhibitor (VMAT2), which is used for the treatment of movement disorders; elagolix, a gonadotropin-releasing hormone (GnRH) antagonist that is in Phase III clinical trial for use in women's health; and opicapone, a catechol-O-methyltransferase inhibitor, which is in Phase III clinical trial that is used for in adjunct therapy and preparations of levodopa/DOPA decarboxylase inhibitors for adult patients with Parkinson's disease.

Read More: Moving Average – How it Helps Investors in Stock Selection

Analyst Recommendations for Neurocrine Biosciences (NASDAQ:NBIX)

Receive News & Ratings for Neurocrine Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Neurocrine Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.